Effect of tissue inhibitor of metalloproteinases 1 and 2 siRNA on the expression of Smad7 protein in hepatic fibrosis rats

您当前的位置：

首页 >

文章列表页 >

Effect of tissue inhibitor of metalloproteinases 1 and 2 siRNA on the expression of Smad7 protein in hepatic fibrosis rats

更新时间：2023-12-18

|

- Effect of tissue inhibitor of metalloproteinases 1 and 2 siRNA on the expression of Smad7 protein in hepatic fibrosis rats
- Journal of Chongqing Medical University Vol. 38, Issue 7, Pages: 919-922(2014)
- 作者机构：
  
  重庆医科大学附属第二医院感染科、教育部感染性疾病分子生物学重点实验室,重庆,400010
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2014，
扫描看全文
Zhang Min, Jiang Yujie, Shi Xiaofeng, et al. Effect of tissue inhibitor of metalloproteinases 1 and 2 siRNA on the expression of Smad7 protein in hepatic fibrosis rats. [J]. Journal of Chongqing Medical University 38(7):919-922(2014)
DOI：

Zhang Min, Jiang Yujie, Shi Xiaofeng, et al. Effect of tissue inhibitor of metalloproteinases 1 and 2 siRNA on the expression of Smad7 protein in hepatic fibrosis rats. [J]. Journal of Chongqing Medical University 38(7):919-922(2014) DOI：

摘要

目的：研究基质金属蛋白酶抑制剂（tissue inhibitor of metalloproteinases，TIMP）1和2的siRNA对CCl4诱导的肝纤维化大鼠Smad7蛋白表达的影响。方法：采用前期构建的TIMP-1 siRNA、TIMP-2 siRNA治疗肝纤维化大鼠的肝脏组织作为研究对象，分为正常组、模型组、阴性对照组（0.25 mg/kg非特异性靶序列）、TIMP-1 siRNA 0. 25 mg/kg组和TIMP-2 siRNA 0.25 mg/kg组。Real-time PCR法检测Smad7的mRNA表达；免疫组织化学、Western blot检测Smad7的蛋白表达。结果：Real-time PCR结果显示TIMP-1 siRNA 0.25 mg/kg组（59.7±3.3）%、TIMP-2 siRNA 0.25 mg/kg组（60.2±3.4）% Smad7的mRNA表达量均较模型组（28.0±1.6）%、阴性对照组（28.6±1.7）%明显增加（P=0.000）；免疫组织化学结果显示TIMP-1 siRNA 0.25mg/kg组（8.55±0.67）、TIMP-2 siRNA 0.25 mg/kg组（8.23±0.85）Smad7的蛋白表达量均较模型组（4.25±0.53）、阴性对照组（4.19±0.55）明显增加（P=0.000）。Western blot结果显示TIMP-1 siRNA 0.25 mg/kg组（0.706±0.039）、TIMP-2 siRNA 0.25 mg/kg组（0.698±0.038）Smad7的蛋白表达量均较模型组（0.278±0.013）、阴性对照组（0.285±0.014）明显增加（P=0.000）。结论：TIMP-1 siRNA、TIMP-2 siRNA对于肝纤维化Smad7的表达有促进作用。

Abstract

Objective：To observe the expression of Smad7 protein in carbon tetrachloride（CCl4）-induced hepatic fibrosis rats treated with TIMP-1 short interference RNA（siRNA） and TIMP-2 siRNA. Methods：The hepatic tissues collected from hepatic fibrosis rats were divided into 5 groups：normal group，model group，negative control group，TIMP-1 siRNA 0.250 mg/kg group and TIMP-2 siRNA 0.250 mg/kg group. The expression of Smad7 was detected by real-time PCR，immunohistochemistry and Western blot. Results：Real-time PCR analysis showed that mRNA expression of Smad7 was significantly higher in TIMP-1 siRNA 0.250 mg/kg group（59.7±3.3）% and TIMP-2 siRNA 0.250 mg/kg group（60.2±3.4）% than in model group（28.0±1.6）% and negative control group（28.6±1.7）%（P=0.000）. Immunohistochemistry showed that protein expression of Smad7 was significantly higher in TIMP-1 siRNA 0.250 mg/kg group（8.55±0.67） and TIMP-2 siRNA 0.250 mg/kg group（8.23±0.85） than in model group（4.25±0.53） and negative control group（4.19±0.55）（P=0.000）. Western blot showed that protein expression of Smad7 was significantly higher in TIMP-1 siRNA 0.250 mg/kg group（0.706±0.039） and TIMP-2 siRNA 0.250 mg/kg group（0.698±0.038） than in the model group（0.278±0.013） and negative control group（0.285±0.014）（P=0.000）. Conclusion：Silencing the TIMP-1 and TIMP-2 with siRNA could be involved in the improvement of the hepatic fibrosis in rats.

关键词

siRNA肝纤维化Smad7基质金属蛋白酶抑制剂

Keywords

siRNAliver fibrosisSmad7tissue inhibitor of metalloproteinases

references

0

Views

1022

下载量

0

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Related Articles

Research progress on the role of SOCS-3 in liver diseases

Effect of liver sinusoidal endothelial cells on hepatic fibrosis and its mechanism

Effect of TIMP-1 siRNA on the expression of TIMP-1 and collagen in rats with liver fibrosis

Effect of GRASP65 expression on proliferation,apoptosis,migration and invasion of gastric cancer cells

Experimental study of romidepsin in reducing liver cirrhosis

Related Author

Yan Yuanzhi

Yang Zhe

Hu Xidan

Ma Kaili

Tang Heng

You Jing

Li Shumin

Li Guiyu

Related Institution

Department of Pharmacy, The NHC Key Laboratory of Drug Addiction Medicine, The First Affiliated Hospital of Kunming Medical University

Department of Pathology, The NHC Key Laboratory of Drug Addiction Medicine, The First Affiliated Hospital of Kunming Medical University

Department of Infectious Diseases and Liver Diseases, The NHC Key Laboratory of Drug Addiction Medicine, The First Affiliated Hospital of Kunming Medical University

Institute of Medical Biology, Chinese Academy of Medical Sciences

Teaching and Research Section of Physiology,School of Basic Medicine,Guangxi University of Traditional Chinese Medicine

⁰